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Background: Subcutaneous specific immunotherapy (SCIT) is an effective treatment attenuating the progression of
allergic asthma. To date, there is a lack of studies investigating the economic consequences of SCIT on health care
expenditures.
Methods: A health-economic piggy-back analysis of SCIT was conducted based on a RCT that enrolled 65 children
and adolescents with allergic asthma. Patients were allocated into two groups: A group receiving SCIT with a high-
dose hypoallergenic house dust mite preparation plus asthma medication and a control group receiving only
asthma medication. For both groups asthma control was achieved before the start of the SCIT treatment and was
maintained during the study. Both, costs and cost-effectiveness of SCIT with the high-dose hypoallergenic house
dust mite preparation were investigated based on total medication costs, incremental medication costs and
treatment effects (measured as lung function), respectively. A bootstrap analysis was performed to validate the
results.
Results: A steady decline in medication costs could be observed in the SCIT group one year after treatment start
compared to the control group. This cost trend became statistically significant 3 years after SCIT started. The
calculated potential savings in the SCIT group correlated with an improved lung function. The distribution of the
bootstrap results revealed that the probability of SCIT having a superior effectiveness compared to the control
group is around 90%.
Conclusion: SCIT with a high-dose hypoallergenic preparation received by children and adolescents suffering from
mite induced allergic asthma reduces the allergic medication intake and has cost-saving effects. Additional costs
associated with SCIT may be completely compensated by drug cost savings 4 years after end of SCIT. Additionally,
SCIT is superior compared to routine care as measured by the lung function that improved in SCIT-treated patients.
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Asthma is one of the most frequent chronic diseases,
with about 300 million patients being affected worldwide
[1]. In children, asthma is even the most frequent
chronic disease [2]. Considering the age-specific preva-
lence of asthma, it becomes apparent that the asthma
prevalence peaks in early childhood and then declines
steadily. The German KIGGS study reported the lifetime
prevalence of asthma in children and adolescents to be
4.7% [3]. However, this number might overestimate the
prevalence, as the answers were derived from self-
responses. Quality of life is reduced in children and ado-
lescents suffering from asthma [4]. The patients often
have a limited ability to participate in physical activities
and are not able to sleep through the night [5]. Asthma
therefore poses a significant burden of disease for the
affected patients. The annual mean sick leave days in
employed asthma patients are around 23 days [6]. In
Germany the total direct costs of asthma were measured
to be about 2.35 billion euro; the costs for sick leave
days caused by asthma were estimated to be 242 million
euro for the year 2006 [7]. This demonstrates that
asthma is an important economic factor for the health
system.
Unlike common antiallergic drugs specific immuno-
therapy (SIT) is the only treatment for allergic patients
that treats the cause of the disease [8]. A specific type of
this therapy is the subcutaneous immunotherapy (SCIT).
Here, allergen extracts are injected subcutaneously [9].
Allergen-specific subcutaneous immunotherapy (SCIT)
is a well-established treatment for mild to moderate
asthma. A Cochrane review demonstrated that SCIT is
an effective treatment for reducing asthma symptoms as
well as medication use [10]. With the decrease in
medication use, we hypothesized that the costs in SCIT-
treated children should decrease as well.
To our knowledge the cost-effectiveness of SCIT to
date in Germany has primarily been demonstrated in
model-based approaches [11,12], as opposed to actual
patient data. This paper therefore aims to analyse the
economic consequences on medication use and the cost-
effectiveness of SCIT in children and adolescents with
asthma using data from a randomized controlled trial.
Methods
Study design
The present health economic piggy back analysis was
conducted based on a randomized, controlled multicen-
ter study (EudraCT-Nr. 2004 – 003892 – 35) including
children and adolescents suffering from allergic asthma
(GINA levels II and III). Before randomization patients’
minimal requirement for the inhaled corticosteroid
(ICS) dose to achieve asthma control was determined in
the baseline phase from September 2005 to February2006 which represents the time of the highest exposure
to house dust mites. Data from patient diaries during
the baseline year build a sound and reliable basis of an
individual patient status prior to the start of treatment.
After achieving asthma control, patients were randomized
into an intervention group, receiving a subcutaneous
specific immunotherapy with house dust mite allergoid
Acaroid® in addition to standard asthma medication, or
into a control group with standard asthma medication
alone. The patients were compared during a mean follow
up period of 3 years. The study including the present
health economic analysis, was approved by an ethics
committee in accordance to the ethical principles that
have their origin in the Declaration of Helsinki, and that
are consistent with GCP and the applicable regulatory
requirements.
The primary endpoint of the study was the change in
the ICS dose steps required to achieve asthma control
(according to GINA [13]) in children treated for two
years with SCIT compared with children on ICS alone.
The ICS dosages in both groups during the third treat-
ment year were described elsewhere [14]. For details on
inclusion and exclusion criteria and detailed statistical
methods see the publication of Zielen et al. 2010 [15].
Economic assessment and outcomes
The economic evaluation was performed using a longi-
tudinal drug cost-analysis, a break even analysis and a
cost-effectiveness analysis.
During the study, patients were asked to keep a diary
about their total medication use (allergic medication as
well as other drugs) and to give information whether a
medication intake was associated with their allergic suf-
fering or whether it was related to other non-allergic dis-
eases. The drug consumption was monetarily valued in
two ways : If it was applicable to extract the exact quan-
tity of drug intake from patients diaries, the monetarily
valuation was calculated using quantity-based prices (e.g.
price per milligram) of the German Rote Liste 2011[16].
If patients documentation on the quantity of the active
ingredients was insufficient, we used official DDD-prices
(defined daily dose) provided annually by the German
Drug-Prescription report [17]. Unfortunately, further re-
source consumption, such as outpatient stays or hospi-
talizations, could not be included in the analysis. Next,
the costs for SCIT with Acaroid® were considered, and
an expected break even-point was calculated. Therefore,
we assumed that potential cost savings, realizable for
SCIT patients in the third treatment year, would be
stable over time after the study. Additionally, we decided
to discount the modelled future savings after the third
treatment year using a discount rate of 3% to consider a
longer time horizon. The underlying SCIT costs per pa-
tient treated with Acaroid® in 2012 were assumed to be
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(perennial therapy, maintenance therapy every 6 weeks,
net prices including 19% value added tax, 16% manufac-
turer sales discount and a price level of August 1, 2009
due to legal price stop).
The effectiveness measure for the following health
economic cost-effectiveness analysis was the lung func-
tion, expressed as the mean annual morning peak flow
(in l/min) after SCIT onset. For cost-effectiveness
analysis we hence calculated the mean annual morning
peak flow during the 3 years after SCIT began in relation
to the mean annual total costs (including SCIT costs)
associated with treatment arms. To get a measure of
uncertainty we used non-parametric bootstrapping [18].
Therefore, the original sample was bootstrapped 1,000
times to obtain 1,000 means for cost and effect
differences that were subsequently plotted in a cost-
effectiveness plane.
Statistical analysis
Socioeconomic data at baseline were analysed using
Student’s t-test for comparing continuous variables and
Chi-Square test for dichotomous variables. Drug costs in
both groups were analysed using Mann–Whitney-U test.
For cost-effectiveness analysis, an analysis of covariance
(ANCOVA) was conducted to adjust all values of costs
and effects for age and the respective peak flow baseline
value. The significance level was defined to be 5% (two-
sided). For inferential statistics, we used SPSS© version




A total of 65 patients were initially recruited and ran-
domized into two groups (33 SCIT, 32 controls). The
mean age of these patients was 10.0±SD 3.1 years in the
SCIT group and 10.6±SD 2, 9 years in the control group.
In both groups, about 30% of patients were female. We
found no significant differences in the average severityFigure 1 Total baseline drug costs per year and outlier analysis (eachof asthma (GINA) or the peak flow measurements be-
fore the SCIT. Differences, however, were detectable
with regard to the allergic-drug costs (434 euro per year
for SCIT, 296 euro per year in controls, p = 0.130) as
well as the resulting total drug costs before the SCIT
intervention started (485 euro per year for SCIT, 345
euro per year in controls, p = 0.083). These differences
were due to the fact that before the intervention started
a total of 6 patients (5 SCIT, 1 control) were identified
as outliers with calculated annual total drug costs of
more than 1,000 euro per year. These patients were ex-
cluded from the following analyses (see Figure 1). The
important baseline characteristics before and after out-
lier exclusion are presented more detailed in Table 1.Drug costs analysis
The descriptive longitudinal total drug cost analysis (see
Figure 2) shows a comparable cost trend in the first year
after SCIT was started. During the further course of time
an increasing cost difference trend was observable
favouring patients in the SCIT group. The total drug
costs (see Table 2) reach a significant difference in year 3
after the intervention began (193 euro 95% CI [114 to
273] for SCIT, 498 euro 95% CI [293 to 702] for con-
trols, p=0.001). This decreasing course of total drug
costs for SCIT-patients was mainly driven by a decrease
in costs of allergic medication intake. A significant group
difference was already reached after the second treat-
ment year. Expectedly, no intervention effect was detect-
able with regard to non-allergic drug costs.Break even calculation
The results of the drug cost analysis indicate cost sav-
ings for patients treated with Acaroid®. If these potential
drug cost-savings will be extrapolated for a longer time
horizon, as it was described in the methods section, the
additional costs of 1,597 euro over the 3-years interven-
tion period that are necessary for realizing SCIT, will be
expected to be compensated by the drug costs savingsdot represents one patient).
Table 1 Baseline characteristics of study participants
Item SCIT Control p-value
Baseline characteristics including outliers (all randomized patients)
n 33 32
Female proportion [n (%)] 11 (33.3%) 10 (31.2%) 0.534
Mean age in years [mean (SD)] 10.0 (3.1) 10.6 (2.9) 0.403
GINA level 2 [n (%)] 26 (78.8%) 26 (81.2%) 0.525
GINA level 3 [n (%)] 7 (21.2%) 6 (18.8%)
Mean peak flow in l/min [mean (SD)] 296 (101) 315 (91) 0.444
Mean annual costs for allergic-drugs before intervention onset in euro [mean (SD)] 434 (332) 296 (220) 0.130
Mean annual costs for non-allergic-drugs before intervention onset in euro [mean (SD)] 51 (87) 50 (98) 0.571
Mean total annual drug costs before intervention onset in euro [mean (SD)] 485 (377) 345 (245) 0.083
Baseline characteristics without outliers (all analysed patients)
n 28 31
Female proportion [n (%)] 8 (28.6%) 10 (32.3%) 0.785
Mean age in years [mean (SD)] 10.4 (3.2) 10.8 (2.8) 0.628
GINA level 2 [n (%)] 21 (75.0%) 25 (80.6%) 0.417
GINA level 3 [n (%)] 7 (25.0%) 6 (19.4%)
Mean asthma level GINA [mean (SD)] 2.25 (0.441) 2.19 (0.402) 0.755
Mean peak flow in l/min [mean (SD)] 308 (105) 317 (91) 0.727
Mean annual costs for allergic-drugs before intervention onset in euro [mean (SD)] 315 (180) 273 (183) 0.443
Mean annual costs for non-allergic-drugs before intervention onset in euro [mean (SD)] 33 (54) 48 (99) 0.974
Mean total annual drug costs before intervention onset in euro [mean (SD)] 349 (192) 322 (209) 0.627
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of triannual SCIT (see Figure 3).Cost-effectiveness analysis
For cost-effectiveness measurement, the SCIT costs were
additionally included and the resulting total costs were
evaluated in relation to the observable treatment effects.
After consideration of SCIT costs, the adjusted total
mean costs per patient over the 3 years treatment dur-
ation differed significantly between the groups (770 euro
95% CI [701 to 839] for SCIT, 383 euro 95% CI [317 to
449] for controls, p<0.001). On the other hand, the use
of SCIT with Acaroid® seems to be associated with su-
perior effectiveness, measured by changes in peak flow
results. The mean annual adjusted morning peak flow
over the 3 years of SCIT intervention shows higher
values for patients receiving SCIT (369 l/min 95% CI
[354 to 385] for SCIT, 334 l/min 95% CI [319 to 348] for
controls, p=0.001). The bootstrapped cost-effectiveness
results are shown in Figure 4. Most of the dots (900 of
1,000) are located in the upper right hand quadrant of
the cost-effectiveness plane, indicating that SCIT is asso-
ciated with additional costs over the 3-years treatment
period, but also with better effectiveness. The probabil-
ity, that SCIT leads to superior effectiveness comparedto controls can be directly derived from the cost-
effectiveness plane and is about 90%.Discussion
The present investigation indicates SCIT with Acaroid®
as a treatment option for children and adolescents suf-
fering from allergic asthma. Thus, allergic medication in-
take and related drug costs can be reduced, and asthma
symptoms improved. After SCIT onset, a cost reduction
trend was observable, showing that allergic medication
costs decrease from year to year. With regard to SCIT
intervention costs, the present analysis indicates, that
these costs will be completely compensated by drug cost
savings about 7 years after SCIT began resp. 4 years after
the end of triannual SCIT.
An important strength of the present analysis is its
embedding in a randomized controlled trial, thus redu-
cing the risk for selection bias and increasing the in-
ternal validity [19]. As yet, there is a lack of comparable
studies on allergic treatment strategies that focus on
economic consequences especially in children. A study,
published by us in 2008, investigated the economic ef-
fects of SCIT using a Markov-model-based approach in
age-stratified patients suffering from allergic rhinitis and
allergic asthma, and reached similar conclusions [12]. In
Table 2 Results on total and allergic/non-allergic drug
costs by year after SCIT onset (analytic) – not involving
SCIT intervention costs
Years after SCIT onset SCIT Control p-value
Total drug costs in euro [mean (95% CI)]
1. year 319 (236 to 402) 364 (262 to 466) 0.716
2. year 250 (168 to 333) 389 (272 to 506) 0.077
3. year 193 (114 to 273) 498 (293 to 702) 0.001
Allergic drug costs in euro [mean (95% CI)]
1. year 270 (197 to 343) 306 (219 to 393) 0.716
2. year 206 (135 to 277) 341 (232 to 451) 0.021
3. year 168 (94 to 242) 453 (249 to 656) 0.002
Non-Allergic drug costs in euro [mean (95% CI)]
1. year 49 (24 to 75) 58 (16 to 100) 0.233
2. year 44 (13 to 75) 47 (7 to 88) 0.262
3. year 25 (2 to 48) 45 (0 to 92) 0.373
Figure 2 Course of total drug costs during the study on daily basis (descriptive) – not involving SCIT intervention costs.
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post intervention from a society’s perspective.
An important point of discussion in the present ana-
lysis is the coverage of costs that could be included for
economic assessment. Since the health economic ana-
lysis was not initially considered in the planning of the
study design, we were not able to get retrospective infor-
mation on resource consumption outside the medication
use. It could be that besides the drug costs savings we
detected in the present analysis, further costs will be
caused in further health care areas. On the other hand,
it seems also plausible, that a reduced need for allergic
medication will have a positive effect on other medical
claims. To get clearness on other cost effects, it would
be desirable to anchorage health economic questions
during the planning phase of future studies.
In the present study asthma in all children had to be
controlled and the study preparation (Acaroid®) helped
to maintain this asthma control. Therefore no emer-
gency visits were observed during the study. Consistently
very poorly controlled asthma increases the risk for fu-
ture severe asthma exacerbations [20,21] and it is well
described in literature that patients with uncontrolled
asthma have a higher risk for emergency visits [22-24].
Emergency visits are associated with higher total and
asthma-related health care costs compared to patients
without exacerbations [25]. Our calculation therefore
might be considered as very conservative taking only
medication costs into account.
Our bootstrapped cost effectiveness results showed
that a mean increase of 35 L/min in morning peak flow
(∼10% of total peak flow) in SCIT-treated children can be
achieved for additional annual costs of about 385 euro.This better peak flow is combined with a fluticasone
propionate reduction for asthma control. This is of im-
portance because the use of inhaled corticosteroids in
children is often seen critical. In a recent study by Kelly
et al. [26] it was shown that the corticosteroid-induced
growth retardation in prepubertal children persisted in
adulthood although it was not progressive or cumulative.
The anti-inflammatory effect of the allergoid preparation
demonstrated by an increased lung function is compar-
able to the effect of inhaled corticosteroids used for
asthma control [27].
For break even calculation we assumed the cost sav-
ings observed in year 3 to be stable over the following
years. This could be criticized as the limited study
Figure 3 Break-even calculation.
Reinhold et al. Clinical and Translational Allergy 2013, 3:30 Page 6 of 8
http://www.ctajournal.com/content/3/1/30duration of 3 years did not allow proving this assump-
tion. Yet, a longer treatment effect is not unlikely. For in-
stance, a systematic review published in 2011 found some
evidence for beneficial long-term effects of SCIT in allergic
children after SCIT termination [28]. Due to the adjusting
for differential timing of costs, using a mean annualFigure 4 Cost-effectiveness results including SCIT costs.discounting-rate of 3% after the third year, the future cost
savings were valued lower than the present. Although the
process of discounting is basically accepted in health
economic research [29] it is consistently a subject of discus-
sion, particularly for long-term health care programs where
benefits mainly appear in the future [28].
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sured the SCIT’s cost-effectiveness. This calculation fo-
cused only on the 3 years study duration. During that
time, the SCIT took place and caused additional inter-
vention costs while future potential cost savings after
year 3 were ignored. Considering a longer time horizon
would lead to less additional costs for SCIT and would
improve the intervention’s cost-effectiveness.Conclusion
SCIT with a hypoallergenic high-dose mite preparation
received by children and adolescents suffering from
mite-allergic asthma reduces the anti-allergic medication
intake of ICS and has cost-saving effects. Additional
costs associated with SCIT may be completely compen-
sated by drug cost savings 4 years after the end of
triannual SCIT. Additional SCIT is superior compared
to only routine care and leads to an improved lung func-
tion while asthma control is maintained.
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